The story of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial launch generated significant profits, the expiration of its intellectual property protection opened the avenue to cheaper competitors, dramatically eroding revenue. This poses a unique risk for firms banking on comparable blockbuster medica

The legacy of Viagra, and its developer copyright, presents a complex case study for investors. Initially a blockbuster drug, generating billions in sales , its patent expiration created a wave of knock-off medications, significantly eroding its position . While some firms may attempt to capitalize on similar conditions , the existing landscape dem